Towards the identification of the correct place for convalescent plasma among COVID-19 therapies.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Subject Terms:
      CONVALESCENT plasma; COVID-19 treatment; COVID-19; COVID-19 pandemic
    • Abstract:
      The article discusses the use of convalescent plasma (CP) as a therapy for COVID-19. CP, which is collected from recovered individuals, has been used in the past to treat infectious disease outbreaks. During the COVID-19 pandemic, CP was the first antibody-based therapy used for emergency treatment. The article highlights a recent double-blinded trial that did not find statistically significant effects on primary outcomes but suggests a potential signal of efficacy for high-titer CP. The authors argue that further research is needed to determine the therapeutic efficacy of CP and optimize its use in future pandemics. [Extracted from the article]
    • Abstract:
      Copyright of Infectious Diseases is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)